S

Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294

Watchlist Manager
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Watchlist
Price: 31.15 CNY -0.1%
Market Cap: 34.7B CNY
Have any thoughts about
Shenzhen Salubris Pharmaceuticals Co Ltd?
Write Note

Shenzhen Salubris Pharmaceuticals Co Ltd
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Shenzhen Salubris Pharmaceuticals Co Ltd
Capital Expenditures Peer Comparison

Comparables:
H
3692
600436
600276
000538
S
688506

Competitive Capital Expenditures Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
S
Shenzhen Salubris Pharmaceuticals Co Ltd
SZSE:002294
Capital Expenditures
-ÂĄ729.6m
CAGR 3-Years
-9%
CAGR 5-Years
-15%
CAGR 10-Years
-10%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Capital Expenditures
-ÂĄ219.6m
CAGR 3-Years
46%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Capital Expenditures
-ÂĄ103.9m
CAGR 3-Years
37%
CAGR 5-Years
-6%
CAGR 10-Years
4%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Capital Expenditures
-ÂĄ1.5B
CAGR 3-Years
-9%
CAGR 5-Years
-25%
CAGR 10-Years
-14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Capital Expenditures
-ÂĄ548.5m
CAGR 3-Years
1%
CAGR 5-Years
6%
CAGR 10-Years
-27%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Capital Expenditures
-ÂĄ81.9m
CAGR 3-Years
-75%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Capital Expenditures?
Capital Expenditures
-729.6m CNY

Based on the financial report for Jun 30, 2024, Shenzhen Salubris Pharmaceuticals Co Ltd's Capital Expenditures amounts to -729.6m CNY.

What is Shenzhen Salubris Pharmaceuticals Co Ltd's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-10%

Over the last year, the Capital Expenditures growth was -38%. The average annual Capital Expenditures growth rates for Shenzhen Salubris Pharmaceuticals Co Ltd have been -9% over the past three years , -15% over the past five years , and -10% over the past ten years .

Back to Top